Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

any focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of operations, liquidity and capital resources, financial prospects, business objectives and strategic goals, drug development plans, timing and results of clinical trials, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market, Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect i
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced today ... th Annual Global Pharma Manufacturing Summit in ... th . The Global Pharma Manufacturing Summit offers ... molecule and biologic pharmaceutical manufacturing. The conference is ... manufacturers face, such as the increasing pressure to ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Markets to 2020 - Novel Therapeutic ... Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics in ...
(Date:8/28/2014)... 2014  Robotic surgery is creating buzz among ... the promise of improved outcomes and the potential ... surgical robots and market pressures to use this ... their robotic surgery training programs and ensure proper ... ECRI Institute ( www.ecri.org ), a nonprofit ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... today announced that the U.S. Patent and Trademark ... key patent application, "Mechanical Method and Apparatus for ... covering the method of the INSORB Skin Closure ... now sold over 500,000 INSORB® Absorbable Skin Staplers ...
... Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent 2Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9
(Date:8/28/2014)... Wilmington, DE (PRWEB) August 28, 2014 Blood's ... murder, gunplay, sex, money and family ties in the heart ... like no other – a story about how disrespect caused ... and limbs on many streets. , The Yayo Boyz and ... leave news reporters speechless and local onlookers in a silent ...
(Date:8/28/2014)... Arizona State University graduate student Anthony Gonzales, co-founder ... one of five finalists in Entrepreneur magazine’s 2014 College ... fourth consecutive year that an ASU student has been ... SafeSIPP, and JJ Tang, co-founder of Vantage Realized, were ... dominated the competition: Three of the five finalists were ...
(Date:8/28/2014)... -- Arguments between parents may damage their relationships with ... more than 200 families were asked to make daily ... each day, mothers and fathers rated the quality of ... On days when parents reported conflict and tension in ... strained, according to the study recently published in the ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ABC television ... the 49th MDA Show of Strength Telethon airing Sunday, ... country to help raise funds and awareness to help ... affected by muscle disease. , Viewers tuning into the ... enjoy heart-felt appeals and introductions from some of the ...
(Date:8/28/2014)... Governor of Yucatán, Rolando Zapata Bello, presented the ... event is organized by the Microcredit Summit Campaign in ... Microenterprise Financing Program ( PRONAFIM ) and will take ... Convention Center Yucatan Siglo XXI in the city of ... to host the 17th Microcredit Summit logistically but especially ...
Breaking Medicine News(10 mins):Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3
... Cannabis was well-tolerated, effective when added to existing ... News) -- Medicinal marijuana helps relieve neuropathic pain ... California, San Diego, School of Medicine study. , ... that wasn,t adequately controlled by opiates or other ...
... ... PALM BEACH, Fla., Aug. 6 The Breakers Palm ... but a company,deeply committed to each employee,s personal well-being. The ... the best of Florida,s,growing season exclusively for The Breakers, 2,300 ...
... Aduromed Begins Next Step in Corporate Evolution, Restructuring the Company ... and Augmenting its Board and Management Team, ... Board: ADRM) a leading manufacturer of medical waste,treatment systems, today ... raise of $3.8 million of new equity capital. As,part of ...
... PLC Systems Inc.,(Amex: PLC ), a company focused ... financial results for the three,and six month periods ended ... were $1,310,000 compared with,$1,932,000 in the second quarter of ... was $671,000, or $0.02 per diluted share, compared to ...
... - Mylan Increases Adjusted EPS Guidance for 2008 to $0.47 ... ... MYL ),today announced its financial results for the three and six months ended,June ... the three months ended June 30,2008, which excludes the impact of certain purchase ...
... ... Second Quarter 2008 Highlights:, ... of $27.4 million, up 86.3% over second quarter 2007,- Gross margin of 25.0%, up from 21.1% in the ... in the first quarter of 2008, - Operating ...
Cached Medicine News:Health News:Medicinal Marijuana Eases Neuropathic Pain in HIV 2Health News:Luxury Resort Operates Seasonal Green Market for 2,300 Staff 2Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 2Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 3Health News:PLC Systems Reports Second Quarter 2008 Results 2Health News:PLC Systems Reports Second Quarter 2008 Results 3Health News:PLC Systems Reports Second Quarter 2008 Results 4Health News:PLC Systems Reports Second Quarter 2008 Results 5Health News:PLC Systems Reports Second Quarter 2008 Results 6Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 2Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 3Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 4Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 5Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 6Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 7Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 8Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 9Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 10Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 11Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 2Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 3Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 4Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 5Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 6Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 7Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 8Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 9
... Healing Shoe offers the most advanced design ... allowing patients to maintain their mobility. Thanks ... even larger portion of the forefoot is ... heads and toes to heal faster. OrthoWedge ...
The choice for inclement weather. This boot provides both closed toe and heel with a moisture resistant vinyl upper....
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
Medicine Products: